Study of QLC1101 for advanced solid tumors with KRAS G12D mutation
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing clinical trials.
This trial tests a new drug, QLC1101, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It may be an option if you have tried other treatments or cannot take them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an advanced solid tumor that cannot be removed by surgery or has spread, and it must have the KRAS G12D mutation.
- You must have tried standard treatment and it didn't work or you can't have it, or you choose not to.
- You must be able to swallow pills and not have any major stomach or bowel problems that affect how the drug is absorbed.
- You must have at least one tumor that can be measured on a CT or MRI scan.
- You must be in fairly good health, able to do most daily activities (ECOG score 0 or 1), and expected to live at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, QLC1101, given with other treatments for people with advanced solid tumors that have a specific change in the KRAS gene called G12D. It aims to see if the combination is safe and helps shrink or slow the cancer.
This study tests a new drug called KQB368 for advanced solid cancers that have a specific genetic change (KRAS G12C or G12S mutation). The drug is designed to target this mutation and may help slow or shrink tumors in patients who don't have other curative treatment options.
This study tests a new experimental drug called QLS5316 for people with advanced solid tumors that have not responded to standard treatments. The drug works like a 'smart bomb'—it seeks out and delivers medicine directly to cancer cells.
This early-stage trial tests a new immunotherapy called CLSP 5282 designed for patients with advanced solid cancers that have a specific genetic change (KRas G12V mutation) and a matching immune marker (HLA-A*03:01). The treatment aims to help your immune system recognize and attack cancer cells.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.